High-sensitive C-reactive protein: Universal prognostic and causative biomarker in heart disease?

Biomarkers in Medicine

Volumn 6, Issue 1, 2012, Pages 19-34

  Rietzschel, Ernst ^b   De Buyzere, Marc ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

atherosclerosis; biomarker; C reactive protein; cardiovascular disease; guidelines; Mendelian randomization; prognosis

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; AORTA ATHEROSCLEROSIS; ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; ATHEROSCLEROTIC PLAQUE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR RISK; COST CONTROL; CYTOKINE RELEASE; DIETARY INTAKE; DISEASE MARKER; DRUG COST; DRUG EFFICACY; HEART DISEASE; HEART INFARCTION; HEART PROTECTION; HUMAN; METABOLIC SYNDROME X; NEOPLASM; NONHUMAN; OUTCOME ASSESSMENT; PHENOTYPIC VARIATION; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SEASONAL VARIATION; STROKE;

ANIMALS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CLINICAL CHEMISTRY TESTS; HEART DISEASES; HUMANS; PROGNOSIS; RISK FACTORS;

EID: 84856593043     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.108     Document Type: Review

References (107)

1. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J. Clin. Invest. 111, 1805-1812 (2003). (Pubitemid 38057722)
2. Brull DJ, Serrano N, Zito F, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 23, 2063-2069 (2003). (Pubitemid 37433201)
3. Tillett WS, Francis T. Serologic reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J. Exp. Med. 52, 561-571 (1930).
4. Mortensen RF. C-reactive protein, inflammation, and innate immunity. Immunol. Res. 24, 163-176 (2001). (Pubitemid 32897076)
5. De Buyzere ML, Rietzschel ER. C-reactive protein's place on the cardiovascular stage: prima ballerina or chorus girl? J. Hypertens. 24, 627-632 (2006).
6. Macleod CM, Avery OT. The occurrence during acute infections of a protein not normally present in the blood. II - Isolation and properties of the reactive protein. J. Exp. Med. 73, 182-190 (1941).
7. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol. 158, 1039-1051 (2001). (Pubitemid 32221796)
8. Eisenhardt SU, Thiele JR, Bannasch H, Stark GB, Peter K. C-reactive protein: how conformational changes influence inflammatory properties. Cell Cycle 8, 3885-3892 (2009).
9. Schwedler SB, Hansen-Hagge T, Reichert M, et al. Monomeric C-reactive protein decreases acetylated LDL uptake in human endothelial cells. Clin. Chem. 55, 1728-1731 (2009).
10. Morrow DA, Rifai N, Antman EM, et al. Serum amyloid A predicts early mortality in acute coronary syndromes: a TIMI 11A substudy. J. Am. Coll. Cardiol. 35, 358-362 (2000). (Pubitemid 30125525)
11. Johnson BD, Kip KE, Marroquin OC, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute-Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation 109, 726-732 (2004). (Pubitemid 38222891)
12. Danesh J, Lewington S, Thompson SG. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 294, 1799-1809 (2005). (Pubitemid 41434626)
13. Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb. Haemost. 95, 511-518 (2006).
14. Piemonti L, Calori G, Lattuada G, et al. Association between plasma monocyte chemoattractant protein-1 concentration and cardiovascular disease mortality in middle-aged diabetic and nondiabetic individuals. Diabetes Care 32, 2105-2110 (2009).
15. Roberts WL, Moulton L, Law TC, et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin. Chem. 47, 418-425 (2001). (Pubitemid 32222454)
16. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance and endothelial dysfunction. A potential role for cytokines originating from adipose tissue? Arterioscler. Thromb. Vasc. Biol. 19, 972-978 (1999). (Pubitemid 29177345)
17. Fröhlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care 23, 1835-1839 (2000).
18. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med. 331, 17-24 (1994).
19. Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. Circulation 113, 38-43 (2006). (Pubitemid 43958486)
20. Verma S, Kuliszewski MA, Li SH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109, 2058-2067 (2004). (Pubitemid 38620212)
21. Vainas T, Stassen FR, de Graaf R, et al. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J. Vasc. Surg. 42, 243-251 (2005). (Pubitemid 41139229)
22. Verma S, Szmitko PE, Ridker PM. C-reactive protein comes of age. Nat. Clin. Pract . Cardiovasc. Med. 2, 29-36 (2005). (Pubitemid 40823207)
23. Verma S, Wang CH, Li SH, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation 106, 913-919 (2002). (Pubitemid 34925323)
24. Verma S, Li SH, Badiwala MV, et al. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105, 1890-1896 (2002). (Pubitemid 34437614)
25. Wang CH, Li SH, Weisel RD, et al. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 107, 1783-1790 (2003). (Pubitemid 36418360)
26. Pasceri V, Cheng JS, Willerson JT, Yeh ET. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs. Circulation 103, 2531-2534 (2001). (Pubitemid 32521959)
27. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol. 158, 1039-1051 (2001). (Pubitemid 32221796)
28. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107, 398-404 (2003).
29. Taylor KE, Giddings JC, van den Berg CW. C-reactive protein-induced in vitro endothelial cell activation is an artefact caused by azide and lipopolysaccharide. Arterioscler. Thromb. Vasc. Biol. 25, 1225-1230 (2005). (Pubitemid 40776613)
30. Kovacs A, Tornvall P, Nilsson R, Tegnér J, Hamsten A, Björkegren J. Human C-reactive protein slows atherosclerosis development in a mouse model with human-like hypercholesterolemia. Proc. Natl Acad. Sci. USA 104, 13768-13773 (2007). (Pubitemid 350003395)
31. Koike T, Kitajima S, Yu Y, et al. Human C-reactive protein does not promote atherosclerosis in transgenic rabbits. Circulation 120, 2088-2094 (2009).
32. Dasu M, Devaraj S, Du Clos T, Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J. Lipid Res. 48, 509-512 (2007). (Pubitemid 46397454)
33. Paul A, Ko KW, Li L, et al. C-reactive protein accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice. Circulation 109, 647-655 (2004). (Pubitemid 38198873)
34. Hirschfield GM, Gallimore JR, Kahan MC, et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. Proc. Natl Acad. Sci. USA 102, 8309-8314 (2005). (Pubitemid 40800085)
35. Teupser D, Weber O, Rao TN, Sass K, Thiery J, Fehling HJ. No reduction of atherosclerosis in C-reactive protein (CRP)-deficient mice. J. Biol. Chem. 286, 6272-6279 (2011).
36. C-Reactive Protein Coronary Heart Disease Genetics Collaboration (CCGC). Association between C reactive protein and coronary heart disease: Mendelian randomisation analysis based on individual participant data. Brit. Med. J. 342, d548 (2011).
37. Allin KH, Nordestgaard BG, Zacho J, Tybjaerg-Hansen A, Bojesen SE. C-reactive protein and the risk of cancer: a Mendelian randomization study. J. Natl Cancer Inst. 102, 202-206 (2010).
38. Dahl M, Vestbo J, Zacho J, Lange P, Tybjærg-Hansen A, Nordestgaard BG. C reactive protein and chronic obstructive pulmonary disease: a Mendelian randomisation approach. Thorax 66, 197-204 (2011).
39. Dehghan A, Dupuis J, Barbalic M, et al. Meta-analysis of genome-wide association studies in >80000 subjects identifies multiple loci for C-reactive protein levels. Circulation 123, 731-738 (2011).
40. Correia LC, Esteves JP. C-reactive protein and outcomes in acute coronary syndromes: a systematic review and meta-analysis. Arq. Bras. Cardiol. 97, 76-85 (2011).
41. Di Napoli M, Elkind MS, Godoy DA, Singh P, Papa F, Popa-Wagner A. Role of C-reactive protein in cerebrovascular disease: a critical review. Expert Rev. Cardiovasc. Ther. 9, 1565-1584 (2011).
42. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin. Chem. 47, 444-450 (2001). (Pubitemid 32222458)
43. Shen J, Ordovas JM. Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents. Clin. Chem. 55, 256-264 (2009).
44. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin. Chem. 43, 52-58 (1997). (Pubitemid 27024390)
45. Miller M, Zhan M, Havas S. High attributable risk of elevated C-reactive protein level to conventional coronary heart disease risk factors: the Third National Health and Nutrition Examination Survey. Arch. Intern. Med. 165, 2063-2068 (2005). (Pubitemid 41434580)
46. Olsen M, Christensen M, Hansen T, et al. High-sensitivity C-reactive protein is only weakly related to cardiovascular damage after adjustment for traditional cardiovascular risk factors. J. Hypertens. 24, 655-661 (2006).
47. Hutchinson WL, Koenig W, Fröhlich M, Sund M, Lowe GD, Pepys MB. Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin. Chem. 46, 934-938 (2000). (Pubitemid 30461263)
48. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107, 499-511 (2003). (Pubitemid 36158056)
49. Marsik C, Kazemi-Shirazi L, Schickbauer T, et al. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin. Chem. 54, 343-349 (2008). (Pubitemid 351302621)
50. Nagano M, Nakamura M, Sato K, Tanaka F, Segawa T, Hiramori K. Association between serum C-reactive protein levels and pulse wave velocity: a population based cross-sectional study in a general population. Atherosclerosis 180, 189-195 (2005).
51. Kullo IJ, Seward JB, Bailey KR, et al. C-reactive protein is related to arterial wave reflection and stiffness in asymptomatic subjects from the community. Am. J. Hypertens. 18, 1123-1129 (2005). (Pubitemid 41139913)
52. Makita S, Nakamura M, Hiramori K. The association of C-reactive protein levels with carotid intima-media complex thickness and plaque formation in the general population. Stroke 36, 2138-2142 (2005). (Pubitemid 41429234)
53. Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Study. Arterioscler. Thromb. Vasc. Biol. 22, 1662-1667 (2002).
54. de Beer FC, Hind CR, Fox KM, Allan RM, Maserei A, Pepys MB. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. Br. Heart J. 47, 239-243 (1982). (Pubitemid 12179920)
55. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 97, 2007-2011 (1998). (Pubitemid 28243661)
56. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836-843 (2000). (Pubitemid 30165206)
57. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 103, 1813-1818 (2001). (Pubitemid 32291421)
58. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med. 347, 1557-1565 (2002). (Pubitemid 35315836)
59. Jager A, van Hinsbergh VW, Kostense PJ, et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn study. Arterioscler. Thromb. Vasc. Biol. 19, 3071-3078 (1999). (Pubitemid 30029838)
60. Lowe GD, Yarnell JW, Rumley A, Bainton D, Sweetnam PM. C-reactive protein, fibrin D-dimers, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler. Thromb. Vasc. Biol. 21, 603-610 (2002). (Pubitemid 32323395)
61. Wilson PW, Nam BH, Pencina M, D'Agostino RB, Benjamin EJ, O'Donnell CJ. C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study. Arch. Intern. Med. 165, 2473-2478 (2005). (Pubitemid 41720008)
62. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 350, 1387-1397 (2004). (Pubitemid 38419992)
63. Kaptoge S, Di Angelantonio E, Lowe G, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis (Emerging Risk Factors Collaboration). Lancet 375, 132-140 (2010).
64. Hemingway H, Philipson P, Chen R, et al. Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med. 7, e1000286 (2010).
65. Best LG, Zhang Y, Lee ET, et al. C-reactive protein as a predictor of cardiovascular risk in a population with a high prevalence of diabetes: the Strong Heart Study. Circulation 112, 1289-1295 (2005). (Pubitemid 41266723)
66. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937-952 (2004). (Pubitemid 39208455)
67. Timpson NJ, Lawlor DA, Harbord RM, et al. C-reactive protein and its role in metabolic syndrome: Mendelian randomization study. Lancet 366, 1954-1959 (2005). (Pubitemid 41713985)
68. Kannel WB, McGee D, Gordon T. A general cardiovascular risk profile: the Framingham Study. Am. J. Cardiol. 38, 46-51 (1976).
69. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 97, 1837-1847 (1998). (Pubitemid 28213628)
70. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 117, 743-753 (2008). (Pubitemid 351640675)
71. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur. Heart J. 24, 987-1003 (2003). (Pubitemid 36712275)
72. Wilson PW, Pencina M, Jacques P, Selhub J, D'Agostino R Sr, O'Donnell CJ. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ. Cardiovasc. Qual. Outcomes 1, 92-97 (2008).
73. Shah T, Casas JP, Cooper JA, et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int. J. Epidemiol. 38, 217-231 (2009).
74. Albert MA, Glynn RJ, Ridker PM. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score. Circulation 108, 161-165 (2003). (Pubitemid 36871297)
75. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 118, 2243-2251 (2008).
76. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 297, 611-619 (2007).
77. Berger JS, Jordan CO, Lloyd-Jones D, Blumenthal RS. Screening for cardiovascular risk in asymptomatic patients. J. Am. Coll. Cardiol. 55, 1169-1177 (2010).
78. Raiko JR, Magnussen CG, Kivimäki M, et al. Cardiovascular risk scores in the prediction of subclinical atherosclerosis in young adults: evidence from the cardiovascular risk in a young Finns study. Eur. J. Cardiovasc. Prev. Rehabil. 17, 549-555 (2010).
79. Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Inflammatory markers, lipoprotein components and risk of major cardiovascular events in 65,005 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Atherosclerosis 213, 299-305 (2010).
80. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N. Engl. J. Med. 355, 2631-2639 (2006). (Pubitemid 44969122)
81. Zethelius B, Berglund L, Sundström J, et al. Use of multiple biomarkers to improve the prediction of death from cardiovascular causes. N. Engl. J. Med. 358, 2107-2116 (2008). (Pubitemid 351679597)
82. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann. Intern. Med. 151, 496-507 (2009).
83. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA 302, 49-57 (2009).
84. Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can. J. Cardiol. 25, 567-579 (2009).
85. Ridker P, Cannon CP, Morrow D, et al. C-reactive protein levels and outcome after statin therapy. N. Engl. J. Med. 352, 20-28 (2005). (Pubitemid 40075677)
86. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N. Engl. J. Med. 359, 2195-2207 (2008).
87. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am. J. Cardiol. 106, 204-209 (2010).
88. Yang EY, Nambi V, Tang Z, et al. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population insights from the ARIC (Atherosclerosis Risk in Communities) study. J. Am. Coll. Cardiol. 54, 2388-2395 (2009).
89. Choudhry NK, Patrick AR, Glynn RJ, Avorn J. The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels. J. Am. Coll. Cardiol. 57, 784-791 (2011).
90. Koenig W, Khuseyinova N, Baumert J, Meisinger C. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin. Chem. 54, 335-342 (2008). (Pubitemid 351302620)
91. Lee S, Choe JW, Kim HK, Sung J. High-sensitivity C-reactive protein and cancer. J. Epidemiol. 21, 161-168 (2011).
92. Siemes C, Visser LE, Coebergh JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J. Clin. Oncol. 24, 5216-5222 (2006). (Pubitemid 46631365)
93. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol. Biomarkers Prev. 15, 381-384 (2006). (Pubitemid 43348407)
94. Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study. Eur. J. Cancer. 42, 704-707 (2006).
95. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J. Clin. Oncol. 27, 2217-2224 (2009).
96. Aleksandrova K, Jenab M, Boeing H, et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am. J. Epidemiol. 172, 407-418 (2010).
97. Tsilidis KK, Branchini C, Guallar E, Helzlsouer KJ, Erlinger TP, Platz EA. C-reactive protein and colorectal cancer risk: a systematic review of prospective studies. Int. J. Cancer 123, 1133-1140 (2008).
98. Galland L. Diet and inflammation. Nutr. Clin. Pract. 25, 634-640 (2010).
99. Estruch R, Sacanella E, Badia E, et al. Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: a prospective randomized crossover trial. Effects of wine on inflammatory markers. Atherosclerosis 175, 117-123 (2004). (Pubitemid 38746918)
100. Avellone G, Di Garbo V, Campisi D, et al. Effects of moderate Sicilian red wine consumption on inflammatory biomarkers of atherosclerosis. Eur. J. Clin. Nutr. 60, 41-47 (2006). (Pubitemid 43731073)
101. Retterstol L, Berge KE, Braaten Ø, Eikvar L, Pedersen TR, Sandvik L. A daily glass of red wine: does it affect markers of inflammation? Alcohol Alcohol. 40, 102-105 (2005). (Pubitemid 40347336)
102. Lee W, Min WK, Chun S, et al. Long-term effects of green tea ingestion on atherosclerotic biological markers in smokers. Clin. Biochem. 38, 84-87 (2005). (Pubitemid 39647660)
103. Steptoe A, Gibson EL, Vuononvirta R, et al. The effects of chronic tea intake on platelet activation and inflammation: a double-blind placebo controlled trial. Atherosclerosis 193, 277-282 (2007). (Pubitemid 47064400)
104. Bahorun T, Luximon-Ramma A, Gunness TK, et al. Black tea reduces uric acid and C-reactive protein levels in humans susceptible to cardiovascular diseases. Toxicology 278, 68-74 (2010).
105. Esposito K, Marfella R, Ciotola M, et al. Effect of a Mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. JAMA 292, 1440-1446 (2004). (Pubitemid 39258336)
106. Michalsen A, Lehmann N, Pithan C, et al. Mediterranean diet has no effect on markers of inflammation and metabolic risk factors in patients with coronary artery disease. Eur. J. Clin. Nutr. 60, 478-485 (2006).
107. The Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT): C-reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. Science News video interview with Professor Peter Sever at the Scientific Sessions of the American Heart Association (AHA) meeting in Chicago, USA, 14-17 November 2010. http://networking.americanheart.org/ video/95